[First intestinal transit bipartition at the Mexican Institute for Social Security]

Obesity is a highly prevalent disease that significantly impacts quality of life and life expectancy. Over the past decades, bariatric surgery has become the gold standard for treating obesity and its comorbidities. In 2006, Santoro et al. described the technique of intestinal transit bipartition (ITB) to enhance neuroendocrine mechanisms of weight loss while minimizing nutritional deficiencies common in other procedures. The objective was to describe the first case of ITB performed in a high specialty center as a surgical treatment for obesity.

A 44-year-old male patient with grade III obesity and comorbidities, including type 2 diabetes mellitus and obstructive sleep apnea. The patient underwent ITB combined with sleeve gastrectomy. During follow-up, a significant reduction in body weight was observed (%EWL of 94.9% at 6 months), without alterations in biochemical parameters such as albumin, hemoglobin, or vitamin D levels. The procedure was safe, with no surgical or postoperative complications.

ITB is a promising surgical technique for the treatment of obesity and its comorbidities, with results comparable to other bariatric procedures. Its neuroendocrine effect favors metabolic control and significant weight loss, while limiting nutritional complications. Initial results highlight its safety and feasibility as a therapeutic alternative, although long-term studies are required to confirm its sustained impact on metabolic health.